A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of
GLPG0634 on the single dose pharmacokinetic profile of midazolam administered in fasted
normal healthy males. Each subject will receive a single oral dose of midazolam (2 mg) on 2
occasions: on Day 1, before dosing with GLPG0634 and on Day 8, after multiple oral doses of
GLPG0634 (daily for 7 days).
Also, the safety and tolerability of multiple oral doses of GLPG0634 co-administered with
midazolam in healthy male subjects will be evaluated.